Needham analyst Gil Blum has maintained their neutral stance on FOLD stock, giving a Hold rating on July 26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum’s rating is based on a combination of factors, including Amicus’s strong financial performance in the second quarter of 2025. The company reported higher-than-expected sales for both Galafold and pom/opf, which surpassed both internal and market estimates. Despite this positive financial outcome, Blum remains cautious about Amicus’s ability to capture significant market share from competitors like Sanofi’s ERTs.
Additionally, while Amicus has maintained its full-year sales growth guidance and is on track to achieve GAAP profitability, there are still uncertainties regarding the competitive landscape. The upcoming advisory committee meeting for sparsentan and its implications for future drug approvals also contribute to the Hold rating. These factors collectively suggest a balanced outlook, warranting a Hold position on the stock.
In another report released on July 26, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $6.50 price target.